Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants

Clicks: 266
ID: 6802
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #120 of 242 articles by views in research reports in clinical cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 242 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Who will benefit from anticoagulant therapy? Use of the CHADS2 score and its variants Atul Singla, Mayank K Mittal, Greg C FlakerDivision of Cardiovascular Medicine, Department of Internal Medicine, University of Missouri, Columbia, MO, USAAbstract: Stroke prevention is a crucial step in the management of atrial fibrillation (AF). The assessment of stroke risk associated with AF varies, depending on the presence of various clinical risk factors (older age, congestive heart failure, diabetes mellitus, hypertension, history of stroke or transient ischemic attack, female sex, or peripheral vascular disease) incorporated in risk stratification models such as CHADS2 and CHA2DS2-VASc. Although these models have modest predictive ability in individual patients, current guidelines advocate the use of a CHA2DS2-VASc risk score to identify very low risk patients who can avoid antithrombotic therapy, as well as all others who can benefit from such therapy. More recently biomarkers and imaging has improved our knowledge of pathophysiology of AF and may further improve risk stratification for thromboprophylaxis in AF patients. These new markers combined with clinical risk scores may enable the development of novel tools to improve clinical risk assessment in AF. In this article, we summarize the recent developments in risk stratification for stroke prevention in AF, including the various schemes and new biomarkers that may lead to improved patient outcomes.Keywords: atrial fibrillation, anticoagulant therapy, CHADS2, risk stratification, CHA2DS2-VASc, biomarkers
Reference Key
atul2014whoresearch Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Atul Singla;Mayank K Mittal;Greg C Flaker and
Journal research reports in clinical cardiology
Year 2014
DOI
10.2147/RRCC.S39091
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.